|
Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations. |
|
|
Stock and Other Ownership Interests - Trovagene |
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; IDEAYA Biosciences; IDEAYA Biosciences; IFM Therapeutics; Immunome; Jazz Pharmaceuticals; Novartis; PureTech; Sequenom; Sotio; Synlogic; Trovagene; Valeant/Dendreon |
Research Funding - Agios (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Fujifilm (Inst); Genentech (Inst); Novartis (Inst); Piqur (Inst); Plexxikon (Inst); Proximagen (Inst); Roche (Inst); Symphogen (Inst) |
Other Relationship - Bio-Rad |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Janssen; Mirati Therapeutics |
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Mirati Therapeutics (Inst); Novartis (Inst) |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Sysmex |
Consulting or Advisory Role - ASLAN Pharmaceuticals; Boehringer Ingelheim; Eisai; Otsuka; PRA health science; Takeda |
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); IQVIA (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda |
Consulting or Advisory Role - AstraZeneca; Loxo; Merck; Novartis; Pfizer; Roche |
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche |
|
|
Research Funding - ADC Therapeutics (Inst); Bayer (Inst); MEI Pharma (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Abbvie; PharmaMar |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche Pharma AG |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MorphoSys; Novartis; Roche; Takeda |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst) |
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst) |